OncoC4 Announces Oral Presentation of a Late-Breaking Abstract on Cesalatamig at the 41st Annual Meeting of SITC

— Global Phase 1/2 Study Data in PD-(L)1–Resistant/Refractory NSCLC to Be Presented on November 7, 2026 — — Clinical Oral Abstract Session 2 Begins at 1:45 PM MST — ROCKVILLE, Md., Oct. 29, 2026 /PRNewswire/ -- OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel...